Earnings call transcript: Scott Technology’s H1 2026 shows steady growth

Scott Technology reported H1 2026 revenue of NZD 128 million, up 5%, with EBITDA rising 7% to NZD 13 million and net profit after tax up 4%; margins remained strong at 29%. Growth was driven by Materials Handling and Logistics (+21%) and Mining (+9%), offset by Protein (-8%) and Appliances (-28%). Management pointed to NZD 177 million in forward work, a planned R&D increase to about 3% of revenue in FY2027, and a NZD 0.04 interim dividend, while keeping a constructive H2 outlook.

Analysis

The important read-through is not the modest top-line beat; it’s the mix shift toward lifecycle services and repeatable aftermarket that raises the terminal quality of earnings. That matters because it should compress revenue cyclicality and lift valuation multiples over time, but only if the company can keep converting project wins into installed-base pull-through rather than one-off recognition. The current setup looks more like an inflection in duration of cash flows than a pure growth story.

The strongest second-order effect is competitive: the larger automation vendors with deeper balance sheets can still win headline projects, but Scott is starting to look more credible in adjacent geographies and end-markets where execution references matter more than scale. If the recent wins turn into a reference loop, the company’s cost of customer acquisition falls and pricing power in service/upgrade work improves. That also creates a small but real squeeze on regional integrators that rely on bespoke projects without a service annuity.

The risk is that the market is underestimating how lumpy H2 can be when project timing is doing most of the work. Protein and Appliances are still vulnerable to capex hesitation, and the company is implicitly relying on a few large conversions to sustain momentum; if even one of those slips by a quarter, the operating leverage story gets pushed out. The other watchpoint is execution capacity: once the order book starts to convert, any bottleneck in manufacturing or commissioning would show up first as margin disappointment, not revenue, so the next two quarters matter more than the headline H1 print.

Contrarian view: consensus may be too focused on the current growth re-acceleration and too slow to price in the optionality from R&D and installed-base monetization. If the service mix continues moving from low-30s toward mid-30s, the stock deserves a higher quality premium even without much faster growth. But if management’s 2030 ramp proves uneven, the equity could still be trapped in a low-multiple industrial box despite better execution.

Key Decisions for Investors

• Long SCT on 3-6 month horizon; thesis is multiple expansion from mix shift to services and better earnings durability. Best entry is on any post-results pullback, with a target of 10-15% upside if H2 conversions hold and service mix keeps rising.
• Pair trade: long SCT / short a more cyclically exposed automation or project-heavy industrial peer for 1-2 quarters. The spread should widen if investors reward recurring revenue quality over lumpy project exposure.
• Buy out-of-the-money calls in SCT around the next 1-2 trading sessions only if liquidity is good; the setup is a catalyst-driven rerate, but execution risk is still high, so premium risk should be capped.
• If you already own SCT, trim only into strength after the next H2 order updates; keep core exposure as long as forward work continues to convert and service growth stays above project revenue growth.
• Avoid chasing the move in Protein-related suppliers until there is evidence the delayed customer investment cycle has turned; this remains a 6-12 month repair, not a next-quarter fix.